Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Mölnlycke makes wound dressings, surgical drapes, gowns, gloves, and hospital hygiene products that hospitals and healthcare workers use to keep patients safe and help wounds heal.
Mölnlycke is a medical supplies company that sells the things hospitals quietly burn through every day: dressings for wounds, drapes and gowns for operating rooms, gloves, and hygiene products. Its customers are hospitals, clinics, and healthcare providers, not regular shoppers. It is headquartered in Gothenburg, Sweden, and it is privately owned.
The business breaks into a few clear parts. Wound care is the big one, where Mölnlycke makes advanced dressings — including its well-known Safetac line, which is designed to stick to the skin around a wound but not to the wound itself, so changing a dressing hurts less. The surgical side supplies drapes, gowns, and gloves that keep operating rooms sterile. A third area covers hospital hygiene and other products, plus the company offers training and support to healthcare staff. Hospitals buy from Mölnlycke for the same reasons they buy from any supplier: reliability, clinical evidence, and safety. The competition is fierce — large rivals like 3M and Johnson & Johnson sell competing wound and surgical products, and buyers constantly push on price. Mölnlycke's edge is its brand trust among nurses and surgeons and its focus on making procedures safer and easier. It is owned by the investment firm Investor AB, which is listed in Sweden, having taken full control in recent years.
The company earns money by selling these disposable products in huge volumes and by keeping customers loyal through quality and training. Because it is private, its detailed finances are not public, but it is a major global player in wound and surgical care. Its business is steady rather than flashy — healthcare demand does not disappear in a recession — but it is exposed to pricing pressure from large hospital buyers and to competitors always trying to win the same contracts.
Saved answer · last researched 15 Nov 2026